The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts.
M Wetzler; S H Bernstein; H Baumann; K M Fries; C Stewart; L Blumenson; M R Baer; G P Herzig; C D Bloomfield; J L Slack (Profiled Author: Maria R Baer)
Department of Hematologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Leukemia & lymphoma 1998;30(5-6):415-31.
The receptor for megakaryocyte growth and development factor (MGDF), also known as thrombopoietin, has recently been cloned. MGDF stimulates platelet production and maturation both in vitro and in vivo. MGDF may thus have a role in attenuating the thrombocytopenia associated with acute myeloid leukemia (AML) and its therapy. However, there is concern that MGDF might induce AML blast proliferation and thereby increase the risk of treatment failure. To address this concern, we studied the expression of c-mpl mRNA and c-Mpl protein by blasts from AML patients. In addition we examined the in vitro effect of MGDF as well as the combined effect of MGDF and granulocyte colony-stimulating factor (G-CSF) or stem cell factor (SCF) on leukemic blast proliferation, recruitment into S-phase, induction of programmed cell death and activation of signal transducers and activators of transcription (STAT) proteins. Our results demonstrate that blasts from a substantial proportion of cases of AML express the receptor at either the mRNA or protein level. Moreover, the function of the MGDF receptor was demonstrated by activation of STAT proteins following exposure to MGDF. Nevertheless, blast proliferation in response to MGDF was rare, and the proliferative effect of MGDF was less than that of G-CSF or SCF. Furthermore, MGDF did not prevent programmed cell death induced by cytarabine. Finally, there appeared to be no correlation between receptor expression by AML blasts and functional response to MGDF. Based on these data, it would appear that clinical trials of MGDF may be undertaken safely in patients with AML.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
M Wetzler; M R BaerLeukemia research 1999;23(2):191-4.
A M Farese; C A Schiffer; T J MacVittieTransfusion medicine reviews 1997;11(4):243-55.
M Wetzler; M R Baer; S H Bernstein; L Blumenson; C Stewart; M Barcos; K Mrózek; A W Block; G P Herzig; C D BloomfieldJournal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2262-8.
Appears in this Publication
Author of this Publication